<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A small group of elderly male patients received attenuated doses of daunomycin, <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C), and 6-thioguanine for treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Three patients had <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), and two had <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (CMMoL) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> five patients had developed severe transfusion requirements for platelets and red blood cells before therapy was begun </plain></SENT>
<SENT sid="3" pm="."><plain>One patient developed <z:mp ids='MP_0001651'>necrosis</z:mp> of the cecum and expired 19 days after therapy, but the other four <z:hpo ids='HP_0000001'>all</z:hpo> showed substantial benefit from treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Three of those patients received multiple courses of chemotherapy which led to improvement in peripheral blood counts in each case </plain></SENT>
<SENT sid="5" pm="."><plain>Duration of responses as noted by improvement in peripheral blood counts compared to pretreatment levels ranged from 1.5 to 9 months </plain></SENT>
<SENT sid="6" pm="."><plain>Despite considerable improvement in peripheral blood parameters, some of the abnormal morphologic features of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> persisted after each course of chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>These results obtained with attenuated chemotherapy schedules in a small group of patients are sufficiently encouraging to warrant an expanded phase II trial, which is under way at the University of Rochester <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center </plain></SENT>
</text></document>